Haemonetics(NYSE) HAE

Haemonetics Corporation makes tools for collecting and managing blood. These products help medical teams save lives during surgeries. The company also provides software to manage blood donor centers.

Tools for Blood and Surgery

• Apheresis: Devices and disposables for collecting plasma and blood components; generated $191.3 million in net revenues for the quarter ended June 27, 2026.
• MedSurg: Hospital tools for vascular closure, clotting assessment, and blood recovery; accounted for $148.1 million in net revenues during the same period.
• Plasma Franchise: Automated collection systems like NexSys PCS and NexLynk software for donor management.
• Hemostasis Management: Systems like TEG that help clinicians assess patient clotting during procedures.

Strategic Shifts and Acquisitions

• Implemented a segment realignment on June 5, 2026, to combine operations into Apheresis and MedSurg units.
• Acquired Attune Medical to expand hospital product offerings.
• Launched a market and regional alignment initiative in May 2025 to focus on high-growth geographies.
• Authorized a $500 million share repurchase program in April 2025.

Global Reach and Focus

Haemonetics operates a global distribution network spanning approximately 90 countries. It uses a mix of direct sales teams and independent distributors to serve medical providers.

Performance by the Numbers

• Net revenues reached $339.4 million for the three-month period ended June 27, 2026, up 5.6% year over year.
• Operating income rose to $57.5 million in the first quarter of fiscal 2027, up 6.7% year over year.
• Cash and cash equivalents totaled $223.4 million as of June 27, 2026.
• Net income was $33.0 million for the quarter ended June 27, 2026, down 3.0% year over year.

Evolution of the Business

Haemonetics has transitioned toward higher-margin hospital technologies while maintaining its core position in plasma collection. This strategy focuses on streamlining global operations and expanding specialized medical device portfolios.